Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is well positioned fundamentally because its post-divestiture portfolio is concentrated in higher-quality Innovative Medicine and MedTech businesses, with the former showing broad-based momentum across 28 billion-dollar platforms and the latter expected to recover as procedure trends normalize. Its growth is being driven by powerful launches and franchises such as Tremfya, Darzalex, Tecvayli, Icotyde, and Inlexzo, while 2Q 2026 sales of $25.3Bn and EPS of $2.90, plus raised 2026 guidance to $100.8Bn-$101.4Bn and $11.60-$11.75, underscore execution. The outlook is further supported by diversified U.S.-led revenue, strong cash generation, and management’s confidence in double-digit growth by the end of the decade, giving it resilience against product roll-offs and litigation noise.

Bears say

Johnson & Johnson is facing a negative outlook because its growth depends heavily on newer launches and pipeline catalysts that could disappoint, including Inlexzo, Icotyde, Rybrevant, Caplyta, and TAR-210, while Stelara continues to decline under biosimilar pressure. The company also posted a Q2'26 MedTech miss, with revenue of $8.93B versus $8.99B consensus and 3.7% y/y operational growth, underscoring that even its diversified platform is not insulated from execution risk. Beyond product and operational uncertainty, U.S. drug pricing reform, pharmaceutical tariffs, changes to direct-to-consumer advertising, and ongoing talc and other product-liability litigation create meaningful earnings, valuation, and volatility risk.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $270.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $270.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.